Changes to the Code
H.R. 1262 · Mikaela Naylon Give Kids a Chance Act · Engrossed The official text as one chamber (House or Senate) passed it.
Passed the House · step 3 of 5
21 U.S.C. § 355 New drugs
1 change the bill asks for here, 1 carried out
- Carried out:
Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is amended by adding at the end the following:
(H) (i) Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 355(j)Abbreviated new drug applications(3)–(4)
Start of § 355 to (j)(3)(H)(iii)(II) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (3)(H)(iv) | (iv) | (iv) | ||
| If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i). | If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i). | |||
| (3)(H)(v) | (v) | (v) | ||
| The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 331(j) of this title, section 552 of title 5, or section 1905 of title 18. | The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 331(j) of this title, section 552 of title 5, or section 1905 of title 18. | |||
| (3)(H) | (H) [inserted: ] | |||
| (3)(H)(i) | (i) [inserted: ] | |||
| [inserted: Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, or for which the Secretary determines there is a scientific justification for an approach that is in vitro, in whole or in part, to be used to demonstrate bioequivalence for a drug if such a drug contains one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, the Secretary shall inform the person whether such drug is qualitatively and quantitatively the same as the listed drug. The Secretary may also provide such information to such a person on the Secretary’s own initiative during the review of an abbreviated application under this subsection for such drug.] | ||||
| (3)(H)(ii) | (ii) [inserted: ] | |||
| [inserted: Notwithstanding section 301(j), if the Secretary determines that such drug is not qualitatively or quantitatively the same as the listed drug, the Secretary shall identify and disclose to the person—] | ||||
| (3)(H)(ii)(I) | (I) [inserted: ] | |||
| [inserted: the ingredient or ingredients that cause such drug not to be qualitatively or quantitatively the same as the listed drug; and] | ||||
| (3)(H)(ii)(II) | (II) [inserted: ] | |||
| [inserted: for any ingredient for which there is an identified quantitative deviation, the amount of such deviation.] | ||||
| (3)(H)(iii) | (iii) [inserted: ] | |||
| [inserted: If the Secretary determines that such drug is qualitatively and quantitatively the same as the listed drug, the Secretary shall not change or rescind such determination after the submission of an abbreviated application for such drug under this subsection unless—] | ||||
| (3)(H)(iii)(I) | (I) [inserted: ] | |||
| [inserted: the formulation of the listed drug has been changed and the Secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness; or] | ||||
| (3)(H)(iii)(II) | (II) [inserted: ] | |||
| [inserted: the Secretary makes a written determination that the prior determination must be changed because an error has been identified.] | ||||
| (3)(H)(iv) | (iv) [inserted: ] | |||
| [inserted: If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).] | ||||
| (3)(H)(v) | (v) [inserted: ] | |||
| [inserted: The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18, United States Code. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 301(j) of this Act, section 552 of title 5, United States Code, or section 1905 of title 18, United States Code.] | ||||
| (4) | (4) | (4) | ||
| Subject to paragraph (5), the Secretary shall approve an application for a drug unless the Secretary finds— | Subject to paragraph (5), the Secretary shall approve an application for a drug unless the Secretary finds— | |||
| (4)(A) | (A) | (A) | ||
| the methods used in, or the facilities and controls used for, the manufacture, processing, and packing of the drug are inadequate to assure and preserve its identity, strength, quality, and purity; | the methods used in, or the facilities and controls used for, the manufacture, processing, and packing of the drug are inadequate to assure and preserve its identity, strength, quality, and purity; | |||
Rest of § 355 unchanged
21 U.S.C. § 355c Research into pediatric uses for drugs and biological products
11 changes the bill asks for here, 6 carried out
- Carried out:
by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively; and
The section already has a provision under this letter or number, so it would have two.
- Carried out:
by striking subparagraph (A) and inserting the following:
(A) In general.— For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of— (i) the drug or biological product for which the application referred to in such paragraph is submitted; or (ii) such …
- Carried out:
Section 505B(e)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(1)) is amended by adding at the end the following:
The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).
. - Not carried out:
Section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(a)(1)) is amended by adding at the end the following:
(C) Rule of construction.— No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be …
The law already reads this way: § 355c(a)(1)(C) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/a/1/C reads as the bill would have it - Not carried out:
in paragraph (3)(C), as redesignated by paragraph (1)(A) of this subsection, by striking
investigations described in this paragraph
and insertinginvestigations referred to in subparagraph (A)
; and“investigations described in this paragraph” isn't in § 355c(a)(3)(C) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“investigations described in this paragraph” not found in /us/usc/t21/s355c/a/3/C - Not carried out:
in paragraph (3)(D), as redesignated by paragraph (1)(A) of this subsection, by striking
the assessments under paragraph (2)(B)
and insertingthe assessments required under paragraph (1)(A)
.“the assessments under paragraph (2)(B)” isn't in § 355c(a)(3)(D) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“the assessments under paragraph (2)(B)” not found in /us/usc/t21/s355c/a/3/D~2 - Carried out:
in paragraph (1), by striking
Beginning 270
and insertingNoncompliance letter.—Beginning 270
; - Carried out:
by striking
The drug or
and insertingEffect of noncompliance.—The drug or
; and - Not carried out:
by striking
(except that the drug or biological product shall not be subject to action under section 303)
and inserting(except that the drug or biological product shall be subject to action under section 303 only if such person demonstrated a lack of due diligence in satisfying the applicable requirement)
; and“(except that the drug or biological product shall not be subject to action under section 303)” isn't in § 355c(d)(2) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“(except that the drug or biological product shall not be subject to action under section 303)” not found in /us/usc/t21/s355c/d/2 - Carried out:
by adding at the end the following:
(3) Limitation.— The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed..
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
Section 505B(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(d)), as amended by subsection (a), is further amended by adding at the end the following:
(4) Due diligence.— Before the Secretary may conclude that a person failed to submit or otherwise meet a requirement as described in the matter preceding paragraph (1), the Secretary shall— (A) issue a noncompliance letter pursuant to paragraph (1); (B) provide such person with …
The law already reads this way: § 355c(d)(4) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/d/4 reads as the bill would have it
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
2 of the 11 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.
3 of the 11 changes this bill asks for here name words or provisions the section had before but doesn't now: the law has changed since the bill was written, so they are not marked.
§ 355c(a)New drugs and biological products(2)–(4)
Start of § 355c to (a)(2)(B)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (2)(B)(iii) | (iii) Information on extrapolation | (iii) Information on extrapolation | ||
| A brief documentation of the scientific data supporting the conclusion under clauses (i) and (ii) shall be included in any pertinent reviews for the application under section 355 of this title or section 262 of title 42. | A brief documentation of the scientific data supporting the conclusion under clauses (i) and (ii) shall be included in any pertinent reviews for the application under section 355 of this title or section 262 of title 42. | |||
| (3) | (3) 1 Molecularly targeted pediatric cancer investigation | (3) 1 Molecularly targeted pediatric cancer investigation | ||
| (3)(A) | (A) In general | (A) In general[inserted: .—] | ||
| For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of— | For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of— | |||
| (3)(A)(i) | (i) | (i) | ||
| the drug or biological product for which the application referred to in such paragraph is submitted; or | the drug or biological product for which the application referred to in such paragraph is submitted; or | |||
| (3)(A)(ii) | (ii) | (ii) | ||
| such drug or biological product used in combination with— | such drug or biological product used in combination with— | |||
| (3)(A)(ii)(I) | (I) | (I) | ||
| an active ingredient of a drug or biological product— | an active ingredient of a drug or biological product— | |||
| (3)(A)(ii)(I)(aa) | (aa) | (aa) | ||
| for which an approved application under section | for which an approved application under section [inserted: 505](j) under this [inserted: Act] or under section [inserted: 351](k) of [inserted: the] [inserted: Public] [inserted: Health Service Act ]is in effect; and | |||
| (3)(A)(ii)(I)(bb) | (bb) | (bb) | ||
| that is determined by the Secretary, after consultation with the applicant, to be part of the standard of care for treating a pediatric cancer; or | that is determined by the Secretary, after consultation with the applicant, to be part of the standard of care for treating a pediatric cancer; or | |||
| (3)(A)(ii)(II) | (II) | (II) | ||
| an active ingredient of a drug or biological product— | an active ingredient of a drug or biological product— | |||
| (3)(A)(ii)(II)(aa) | (aa) | (aa) | ||
| for which an approved application under section | for which an approved application under section [inserted: 505](b) of this [inserted: Act] or section [inserted: 351](a) of [inserted: the] [inserted: Public] [inserted: Health Service Act ]to treat an adult cancer is in effect and is held by the same person submitting the application under paragraph (1)(B); and | |||
| (3)(A)(ii)(II)(bb) | (bb) | (bb) | ||
| that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer. | that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer. | |||
| (3)(B) | (B) [inserted: Additional requirements.—] | |||
| (3)(B)(i) | (i) [inserted: Design of investigation.—] | |||
| [inserted: A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.] | ||||
| (3)(B)(ii) | (ii) [inserted: Limitation.—] | |||
| [inserted: An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—] | ||||
| (3)(B)(ii)(I) | (I) [inserted: ] | |||
| [inserted: a single new active ingredient; or] | ||||
| (3)(B)(ii)(II) | (II) [inserted: ] | |||
| [inserted: more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.] | ||||
| (3)(B)(iii) | (iii) [inserted: Results of already-completed preclinical studies of application drug.—] | |||
| [inserted: With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.] | ||||
| (3)(B)(iv) | (iv) [inserted: Rule of construction regarding inactive ingredients.—] | |||
| [inserted: With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.] | ||||
| (3)(C) | [inserted: (C)] Additional requirements | |||
| (3)(C)(i) | (i) Design of investigation | (i) Design of investigation | ||
| A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling. | A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling. | |||
| (3)(C)(ii) | (ii) Limitation | (ii) Limitation | ||
| An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either— | An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either— | |||
| (3)(C)(ii)(I) | (I) | (I) | ||
| a single new active ingredient; or | a single new active ingredient; or | |||
| (3)(C)(ii)(II) | (II) | (II) | ||
| more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer. | more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer. | |||
| (3)(C)(iii) | (iii) Results of already-completed preclinical studies of application drug | (iii) Results of already-completed preclinical studies of application drug | ||
| With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted. | With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted. | |||
| (3)(C)(iv) | (iv) Rule of construction regarding inactive ingredients | (iv) Rule of construction regarding inactive ingredients | ||
| With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination. | With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination. | |||
| (3)(D) | [inserted: (D)] Extrapolation of data | |||
| Paragraph (2)(B) shall apply to investigations referred to in subparagraph (A) to the same extent and in the same manner as paragraph (2)(B) applies with respect to the assessments required under paragraph (1)(A). | Paragraph (2)(B) shall apply to investigations referred to in subparagraph (A) to the same extent and in the same manner as paragraph (2)(B) applies with respect to the assessments required under paragraph (1)(A). | |||
| (3)(D) | (D) Deferrals and waivers | (D) Deferrals and waivers | ||
| Deferrals and waivers under paragraphs (4) and (5) shall apply to investigations described in this paragraph to the same extent and in the same manner as such deferrals and waivers apply with respect to the assessments required under paragraph (1)(A). | Deferrals and waivers under paragraphs (4) and (5) shall apply to investigations described in this paragraph to the same extent and in the same manner as such deferrals and waivers apply with respect to the assessments required under paragraph (1)(A). | |||
| (4) | (4) Deferral | (4) Deferral | ||
§ 355c(d)Submission of assessments and reports on the investigation(1)–(2)
(a)(4)(A)–(c)(2) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (d) | (d) Submission of assessments and reports on the investigation | (d) Submission of assessments and reports on the investigation | ||
| If a person fails to submit a required assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), fails to meet the applicable requirements in subsection (a)(4), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply: | If a person fails to submit a required assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), fails to meet the applicable requirements in subsection (a)(4), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply: | |||
| (1) | (1) Noncompliance letter | (1) Noncompliance letter | ||
| Beginning 270 days after July 9, 2012, the Secretary shall issue a non-compliance letter to such person informing them of such failure to submit or meet the requirements of the applicable subsection. Such letter shall require the person to respond in writing within 45 calendar days of issuance of such letter. Such response may include the person’s request for a deferral extension if applicable. Such letter and the person’s written response to such letter shall be made publicly available on the Internet Web site of the Food and Drug Administration 60 calendar days after issuance, with redactions for any trade secrets and confidential commercial information. If the Secretary determines that the letter was issued in error, the requirements of this paragraph shall not apply. The Secretary shall inform the Pediatric Advisory Committee of letters issued under this paragraph and responses to such letters. | [inserted: Noncompliance letter.—]Beginning 270 days after July 9, 2012, the Secretary shall issue a non-compliance letter to such person informing them of such failure to submit or meet the requirements of the applicable subsection. Such letter shall require the person to respond in writing within 45 calendar days of issuance of such letter. Such response may include the person’s request for a deferral extension if applicable. Such letter and the person’s written response to such letter shall be made publicly available on the Internet Web site of the Food and Drug Administration 60 calendar days after issuance, with redactions for any trade secrets and confidential commercial information. If the Secretary determines that the letter was issued in error, the requirements of this paragraph shall not apply. The Secretary shall inform the Pediatric Advisory Committee of letters issued under this paragraph and responses to such letters. | |||
| (2) | (2) Effect of noncompliance | (2) Effect of noncompliance | ||
| The drug or biological product that is the subject of an assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), applicable requirements in subsection (a)(4), or request for approval of a pediatric formulation, may be considered misbranded solely because of that failure and subject to relevant enforcement action (except that the drug or biological product shall be subject to action under section 333 of this title only if such person demonstrated a lack of due diligence in satisfying the applicable requirement), but such failure shall not be the basis for a proceeding— | [inserted: Effect of noncompliance.—]The drug or biological product that is the subject of an assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), applicable requirements in subsection (a)(4), or request for approval of a pediatric formulation, may be considered misbranded solely because of that failure and subject to relevant enforcement action (except that the drug or biological product shall be subject to action under section 333 of this title only if such person demonstrated a lack of due diligence in satisfying the applicable requirement), but such failure shall not be the basis for a proceeding— | |||
| (2)(A) | (A) | (A) | ||
| to withdraw approval for a drug under section 355(e) of this title; or | to withdraw approval for a drug under section 355(e) of this title; or | |||
| (2)(B) | (B) | (B) | ||
| to revoke the license for a biological product under section 262 of title 42. | to revoke the license for a biological product under section 262 of title 42. |
§ 355c(d)–(e)
(d)(3)–(4) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (d)(4)(B) | (B) | (B) | ||
| provide such person with a 45-day period beginning on the date of receipt of such noncompliance letter to respond in writing as set forth in such paragraph; and | provide such person with a 45-day period beginning on the date of receipt of such noncompliance letter to respond in writing as set forth in such paragraph; and | |||
| (d)(4)(C) | (C) | (C) | ||
| after reviewing such written response, determine whether the person demonstrated a lack of due diligence in satisfying such requirement. | after reviewing such written response, determine whether the person demonstrated a lack of due diligence in satisfying such requirement. | |||
| (d)(3) | (3) [inserted: Limitation.—] | |||
| [inserted: The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed.] | ||||
| (e) | (e) Pediatric study plans | (e) Pediatric study plans | ||
| (e)(1) | (1) In general | (1) In general | ||
| An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2) or the investigation described in subsection (a)(3). The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).1 | An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2) or the investigation described in subsection (a)(3). The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).1[inserted: The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).] | |||
| (e)(2) | (2) Timing; content; meetings | (2) Timing; content; meetings | ||
| (e)(2)(A) | (A) Timing | (A) Timing | ||
| An applicant shall submit the initial pediatric study plan under paragraph (1)— | An applicant shall submit the initial pediatric study plan under paragraph (1)— | |||
Rest of § 355c unchanged
21 U.S.C. § 355c–1 Report
4 changes the bill asks for here, 2 carried out
- Carried out:
in paragraph (11), by striking the semicolon at the end and inserting , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions
;
; - Not carried out:
in paragraph (15), by striking
and
at the end;The bill strikes “and” at the end of § 355c–1(b)(15), but the text there doesn't end with it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“and” is not at the end of /us/usc/t21/s355c–1/b/15 - Not carried out:
in paragraph (16), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 355c–1(b)(16), but the text there doesn't end with it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“.” is not at the end of /us/usc/t21/s355c–1/b/16 - Carried out:
by adding at the end the following:
(17) a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
2 of the 4 changes this bill asks for here name words or provisions the section had before but doesn't now: the law has changed since the bill was written, so they are not marked.
§ 355c–1(b)Contents(10)–(12)
Start of § 355c–1 to (b)(9) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (10) | (10) | (10) | ||
| an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 355a and 355c of this title; | an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 355a and 355c of this title; | |||
| (11) | (11) | (11) | ||
| an assessment of the impact of the amendments to such section 355c of this title made by the FDA Reauthorization Act of 2017 on pediatric research and labeling of drugs and biological products and pediatric labeling of molecularly targeted drugs and biological products for the treatment of cancer, including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions; | an assessment of the impact of the amendments to such section 355c of this title made by the FDA Reauthorization Act of 2017 on pediatric research and labeling of drugs and biological products and pediatric labeling of molecularly targeted drugs and biological products for the treatment of cancer, including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions[inserted: , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions]; | |||
| (12) | (12) | (12) | ||
| an assessment of the efforts of the Secretary to implement the plan developed under section 505C–1 of the Federal Food, Drug, and Cosmetic Act,1 regarding earlier submission of pediatric studies under sections 355a and 355c of this title and section 262(m) of title 42, including— | an assessment of the efforts of the Secretary to implement the plan developed under section 505C–1 of the Federal Food, Drug, and Cosmetic Act,1 regarding earlier submission of pediatric studies under sections 355a and 355c of this title and section 262(m) of title 42, including— | |||
| (12)(A) | (A) | (A) | ||
| the average length of time after the approval of an application under section 355(b)(1) of this title or section 262(a) of title 42 before studies conducted pursuant to such section 355a of this title, 355c of this title, or section 262(m) of title 42 are completed, submitted, and incorporated into labeling; | the average length of time after the approval of an application under section 355(b)(1) of this title or section 262(a) of title 42 before studies conducted pursuant to such section 355a of this title, 355c of this title, or section 262(m) of title 42 are completed, submitted, and incorporated into labeling; |
§ 355c–1(b)–(c)
(b)(12)(B)–(15) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(16) | (16) | (16) | ||
| the Secretary’s assessment of the overall impact of the amendments made by section 504 of the FDA Reauthorization Act of 2017 on the conduct and effectiveness of pediatric cancer research and the orphan drug program, as well any subsequent recommendations; and | the Secretary’s assessment of the overall impact of the amendments made by section 504 of the FDA Reauthorization Act of 2017 on the conduct and effectiveness of pediatric cancer research and the orphan drug program, as well any subsequent recommendations; and | |||
| (b)(17) | (17) | (17) | ||
| a listing of penalties, settlements, or payments under section 333 of this title for failure to comply with requirements under such section 355c of this title, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed. | a listing of penalties, settlements, or payments under section 333 of this title for failure to comply with requirements under such section 355c of this title, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed. | |||
| (b)(17) | (17) [inserted: ] | |||
| [inserted: a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed.] | ||||
| (c) | (c) Stakeholder comment | (c) Stakeholder comment | ||
| At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products. | At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products. | |||
21 U.S.C. § 360cc Protection for drugs for rare diseases or conditions
5 changes the bill asks for here, 1 carried out
- Not carried out:
in subsection (a), in the matter following paragraph (2), by striking
same disease or condition
and insertingsame approved use or indication within such rare disease or condition
;“same disease or condition” isn't in § 360cc(a) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“same disease or condition” not found in /us/usc/t21/s360cc/a - Not carried out:
in the matter preceding paragraph (1), by striking
same rare disease or condition
and insertingsame approved use or indication for which such 7-year period applies to such already approved or licensed drug
; and“same rare disease or condition” isn't in § 360cc(b) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“same rare disease or condition” not found in /us/usc/t21/s360cc/b - Not carried out:
in paragraph (1), by inserting
, relating to the approved use or indication,
afterthe needs
;The law already reads this way: § 360cc(b)(1) already has “, relating to the approved use or indication,”.
Technical detail
already reads “, relating to the approved use or indication,” at that place in /us/usc/t21/s360cc/b/1 - Not carried out:
in subsection (c)(1), by striking
same rare disease or condition as the already approved drug
and insertingsame use or indication for which the already approved or licensed drug was approved or licensed
; and“same rare disease or condition as the already approved drug” isn't in § 360cc(c)(1) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“same rare disease or condition as the already approved drug” not found in /us/usc/t21/s360cc/c/1 - Carried out:
by adding at the end the following:
(f) Approved use or indication defined.— In this section, the term “approved use or indication” means the use or indication approved under section 505 of this Act or licensed under section 351 of the Public Health Service Act for a drug designated under section 526 for a rare disease or condition..
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
1 of the 5 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.
3 of the 5 changes this bill asks for here name words or provisions the section had before but doesn't now: the law has changed since the bill was written, so they are not marked.
§ 360cc(e)–(f)
Start of § 360cc to (e)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (e)(2) | (2) | (2) | ||
| upon granting exclusive approval or licensure under subsection (a) on the basis of a demonstration of clinical superiority as described in subsection (c), shall publish a summary of the clinical superiority findings. | upon granting exclusive approval or licensure under subsection (a) on the basis of a demonstration of clinical superiority as described in subsection (c), shall publish a summary of the clinical superiority findings. | |||
| (f) | (f) Approved use or indication defined | (f) Approved use or indication defined | ||
| In this section, the term “approved use or indication” means the use or indication approved under section 355 of this title or licensed under section 262 of title 42 for a drug designated under section 360bb of this title for a rare disease or condition. | In this section, the term “approved use or indication” means the use or indication approved under section 355 of this title or licensed under section 262 of title 42 for a drug designated under section 360bb of this title for a rare disease or condition. | |||
| (f) | (f) [inserted: Approved use or indication defined.—] | |||
| [inserted: In this section, the term “approved use or indication” means the use or indication approved under section 505 of this Act or licensed under section 351 of the Public Health Service Act for a drug designated under section 526 for a rare disease or condition.] | ||||
21 U.S.C. § 360ff Priority review to encourage treatments for rare pediatric diseases
2 changes the bill asks for here, 1 carried out
- Not carried out:
Paragraph (5) of section 529(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)) is amended by striking
December 20, 2024, unless
and all that follows through the period at the end and insertingSeptember 30, 2029.
.“December 20, 2024, unless” isn't in § 360ff(b)(5) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“December 20, 2024, unless” not found in /us/usc/t21/s360ff/b/5 - Carried out:
Section 529(c)(4) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(c)(4)) is amended by striking subparagraph (A) and inserting the following:
(A) In general.— The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 505(b)(1) or section 351(a) of the Public Health Service Act for which the priority review voucher is used. All other user fees …
1 of the 2 changes this bill asks for here names words or provisions the section had before but doesn't now: the law has changed since the bill was written, so it is not marked.
§ 360ff(c)Priority review user fee(3)–(4)
Start of § 360ff to (c)(2)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (3) | (3) Annual fee setting | (3) Annual fee setting | ||
| The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2012, the amount of the priority review user fee for that fiscal year. | The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2012, the amount of the priority review user fee for that fiscal year. | |||
| (4) | (4) Payment | (4) Payment | ||
| (4)(A) | (A) In general | (A) In general[inserted: .—] | ||
| The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section | The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section [inserted: 505](b)(1) or section 351(a) of the Public Health Service Act for which the priority review voucher is used. All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law. | |||
| (4)(B) | (B) Complete application | (B) Complete application | ||
| An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary’s procedures for paying such fees. | An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary’s procedures for paying such fees. | |||
| (4)(C) | (C) No waivers, exemptions, reductions, or refunds | (C) No waivers, exemptions, reductions, or refunds | ||
| The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section. | The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section. |
Rest of § 360ff unchanged
42 U.S.C. § 274 Organ procurement and transplantation network
8 changes the bill asks for here, 1 carried out
- Not carried out:
in clause (i), by striking
, and
and inserting; and
; and“, and” isn't in § 274(b)(2)(A)(i) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“, and” not found in /us/usc/t42/s274/b/2/A/i - Not carried out:
in clause (ii)
,
by striking the comma at the end and inserting a semicolon;
The bill strikes “,” at the end of § 274(b)(2)(A)(ii), but the text there doesn't end with it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“,” is not at the end of /us/usc/t42/s274/b/2/A/ii - Not carried out:
in subparagraph (C), by striking
twenty-four-hour telephone service
and inserting24-hour telephone or information technology service
;“twenty-four-hour telephone service” isn't in § 274(b)(2)(C) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“twenty-four-hour telephone service” not found in /us/usc/t42/s274/b/2/C - Not carried out:
in each of subparagraphs (B) through (M)
,
by striking the comma at the end and inserting a semicolon;
The bill strikes “,” at the end of § 274(b)(2)(B), but the text there doesn't end with it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“,” is not at the end of /us/usc/t42/s274/b/2/B - Not carried out:
in subparagraph (N), by striking
transportation, and
and insertingtransportation;
;“transportation, and” isn't in § 274(b)(2)(N) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“transportation, and” not found in /us/usc/t42/s274/b/2/N - Not carried out:
in subparagraph (O), by striking the period and inserting a semicolon
;
and“.” isn't in § 274(b)(2)(O) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“.” not found in /us/usc/t42/s274/b/2/O - Not carried out:
by adding at the end the following:
(P) encourage the integration of electronic health records systems through application programming interfaces (or successor technologies) among hospitals, organ procurement organizations, and transplant centers, including the use of automated electronic hospital referrals and …
The law already reads this way: § 274(b)(2)(P) is already as the bill would have it.
Technical detail
already there: /us/usc/t42/s274/b/2/P reads as the bill would have it - Carried out:
by adding at the end the following:
(d) Registration fees.— (1) In general.— The Secretary may collect registration fees from any member of the Organ Procurement and Transplantation Network for each transplant candidate such member places on the list described in subsection (b)(2)(A)(i). Such registration fees …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
1 of the 8 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.
6 of the 8 changes this bill asks for here name words or provisions the section had before but doesn't now: the law has changed since the bill was written, so they are not marked.
§ 274(d)–(d)
Start of § 274 to (d)(5)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (d)(5)(B) | (B) | (B) | ||
| submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Finance of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report on such review, including related recommendations, as applicable. | submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Finance of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report on such review, including related recommendations, as applicable. | |||
| (d)(6) | (6) Sunset | (6) Sunset | ||
| The authority to collect registration fees under paragraph (1) shall expire on the date that is 3 years after February 3, 2026. | The authority to collect registration fees under paragraph (1) shall expire on the date that is 3 years after February 3, 2026. | |||
| (d) | (d) [inserted: Registration fees.—] | |||
| (d)(1) | (1) [inserted: In general.—] | |||
| [inserted: The Secretary may collect registration fees from any member of the Organ Procurement and Transplantation Network for each transplant candidate such member places on the list described in subsection (b)(2)(A)(i). Such registration fees shall be collected and distributed only to support the operation of the Organ Procurement and Transplantation Network. Such registration fees are authorized to remain available until expended.] | ||||
| (d)(2) | (2) [inserted: Collection.—] | |||
| [inserted: The Secretary may collect the registration fees under paragraph (1) directly or through awards made under subsection (b)(1)(A).] | ||||
| (d)(3) | (3) [inserted: Distribution.—] | |||
| [inserted: Any amounts collected under this subsection shall—] | ||||
| (d)(3)(A) | (A) [inserted: ] | |||
| [inserted: be credited to the currently applicable appropriation, account, or fund of the Department of Health and Human Services as discretionary offsetting collections; and] | ||||
| (d)(3)(B) | (B) [inserted: ] | |||
| [inserted: be available, only to the extent and in the amounts provided in advance in appropriations Acts, to distribute such fees among awardees described in subsection (b)(1)(A).] | ||||
| (d)(4) | (4) [inserted: Transparency.—] | |||
| [inserted: The Secretary shall—] | ||||
| (d)(4)(A) | (A) [inserted: ] | |||
| [inserted: promptly post on the website of the Organ Procurement and Transplantation Network—] | ||||
| (d)(4)(A)(i) | (i) [inserted: ] | |||
| [inserted: the amount of registration fees collected under this subsection from each member of the Organ Procurement and Transplantation Network; and] | ||||
| (d)(4)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: a list of activities such fees are used to support; and] | ||||
| (d)(4)(B) | (B) [inserted: ] | |||
| [inserted: update the information posted pursuant to subparagraph (A), as applicable for each calendar quarter for which fees are collected under paragraph (1).] | ||||
| (d)(5) | (5) [inserted: GAO review.—] | |||
| [inserted: Not later than 2 years after the date of enactment of this subsection, the Comptroller General of the United States shall, to the extent data are available—] | ||||
| (d)(5)(A) | (A) [inserted: ] | |||
| [inserted: conduct a review concerning the activities under this subsection; and] | ||||
| (d)(5)(B) | (B) [inserted: ] | |||
| [inserted: submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Finance of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report on such review, including related recommendations, as applicable.] | ||||
| (d)(6) | (6) [inserted: Sunset.—] | |||
| [inserted: The authority to collect registration fees under paragraph (1) shall expire on the date that is 3 years after the date of enactment of the Mikaela Naylon Give Kids a Chance Act.] | ||||
21 U.S.C. § 333 Penalties
The bill's words for this section
- Not carried out:
Section 303(f)(4)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333(f)(4)(A)) is amended by striking
or 505–1
and inserting505–1, or 505B
.“or 505–1” isn't in § 333(f)(4)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“or 505–1” not found in /us/usc/t21/s333/f/4/A
42 U.S.C. § 284m Program for pediatric studies of drugs
The bill's words for this section
- Carried out:
Section 409I(d)(1) of the Public Health Service Act (42 U.S.C. 284m(d)(1)) is amended by striking
section,
and all that follows through the period at the end and insertingsection, $25,000,000 for each of fiscal years 2026 through 2028.
.
42 U.S.C. § 1395iii Medicare Improvement Fund
The change this bill asks for here names words or provisions the section had before but doesn't now: the law has changed since the bill was written, so it is not marked.
The bill's words for this section
- Not carried out:
Section 1898(b)(1) of the Social Security Act (42 U.S.C. 1395iii(b)(1)) is amended by striking
$1,403,000,000
and inserting$2,622,000,000
.“$1,403,000,000” isn't in § 1395iii(b)(1) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“$1,403,000,000” not found in /us/usc/t42/s1395iii/b/1